Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.

Trial Details

NCT ID
NCT07073365
Phase
PHASE2
Sponsor
Pusan National University Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Local Therapy (Surgery or Radiotherapy)
Locations (sample)
  • Busan, South Korea|35.10168,129.03004

Key Eligibility Criteria

  • Participants must meet all of the following criteria to be eligible:
  • Age ≥ 20 years at the time of consent.
  • Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).
  • Presence of activating EGFR mutation (exon 19 deletion or L858R).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →